Cited by 7,449Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction ResearchCancer, Lipids, and Metabolism

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia

Open access

Shepherd, James, Cobbe, Stuart M., Ford, Ian, Isles, Christopher G., Lorimer, A. Ross, Macfarlane, Peter W., McKillop, James H., Packard, Christopher J.·1995·New England Journal of Medicine

DOI 10.1056/nejm199511163332001

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Lowering the blood cholesterol level may reduce the risk of coronary heart disease. This double-blind study was designed to determine whether the administration of pravastatin to men with hypercholesterolemia and no history of myocardial infarction reduced the combined incidence of nonfatal myocardial infarction and death from coronary heart disease. METHODS: We randomly assigned 6595 men, 45 to 64 years of age, with a mean (+/- SD) plasma cholesterol level of 272 +/- 23 mg per deciliter (7.0 +/- 0.6 mmol per liter) to receive pravastatin (40 mg each evening) or placebo. The average follow-up period was 4.9 years. Medical records, electrocardiographic recordings, and the national death registry were used to determine the clinical end points. RESULTS: Pravastatin lowered plasma cholesterol levels by 20 percent and low-density-lipoprotein cholesterol levels by 26 percent, whereas there was no change with placebo. There were 248 definite coronary events (specified as nonfatal myocardial infarction or death from coronary heart disease) in the placebo group, and 174 in the pravastatin group (relative reduction in risk with pravastatin, 31 percent; 95 percent confidence interval, 17 to 43 percent; P < 0.001). There were similar reductions in the risk of definite nonfatal myocardial infarctions (31 percent reduction, P < 0.001), death from coronary heart disease (definite cases alone: 28 percent reduction, P = 0.13; definite plus suspected cases: 33 percent reduction, P = 0.042), and death from all cardiovascular causes (32 percent reduction, P = 0.033). There was no excess of deaths from noncardiovascular causes in the pravastatin group. We observed a 22 percent reduction in the risk of death from any cause in the pravastatin group (95 percent confidence interval, 0 to 40 percent; P = 0.051). CONCLUSIONS: Treatment with pravastatin significantly reduced the incidence of myocardial infarction and death from cardiovascular causes without adversely affecting the risk of death from noncardiovascular causes in men with moderate hypercholesterolemia and no history of myocardial infarction.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejm199511163332001

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
The Lipid Research Clinics Coronary Primary Prevention Trial Results: I. Reduction in Incidence of Coronary Heart Disease
(1984) · JAMA · doi:10.1001/jama.1984.03340270029025 · Cited by 2,747
MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party.
(1985) · BMJ · doi:10.1136/bmj.291.6488.97 · Cited by 1,491
Modelling Survival Data in Medical Research
Collett, D. (1994) · Springer eBooks · doi:10.1007/978-1-4899-3115-3 · Cited by 1,064
A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators.
Oliver, M., Heady, J., Morris, J. N., Cooper, J., Geizerova, H., Gyárfás, I., Green, K., Strasser, T., Macfie, W. G., Scott, E., et al. (1978) · Heart · doi:10.1136/hrt.40.10.1069 · Cited by 1,047
Modelling Survival Data in Medical Research.
McLachlan, G. J., & Collett, D. (1994) · Biometrics · doi:10.2307/2533471 · Cited by 1,023
Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS).
Jukema, J., Bruschke, A. V., van Boven, A. J., Reiber, J., Bal, E., Zwinderman, A., Jansen, H., Boerma, G., van Rappard, F. M., & Kong, L. I. (1995) · Circulation · doi:10.1161/01.cir.91.10.2528 · Cited by 911
Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group.
Furberg, C. D., Adams, H. P., Applegate, W. B., Byington, R. P., Espeland, M. A., Hartwell, T., Hunninghake, D. B., Lefkowitz, D. S., Probstfield, J. L., & Riley, W. A. (1994) · Circulation · doi:10.1161/01.cir.90.4.1679 · Cited by 865

Show all 26 references

Research works printed but not linked: 4

10.1001/jama.251.3.351 · DOI · Paper page
1994, Lancet, 344, 1383
1992, Nutr Metab Cardiovasc Dis, 2, 113
Macfarlane PW, 1990, Eur Heart J, 11, 411

Sorted by citations

Items 801–900 of 1,060

Inflammatory cytokines and the possible immunological role for lipoproteins in chronic heart failure
Rauchhaus, M., Koloczek, V., Volk, H., Kemp, M., Niebauer, J., Francis, D. P., Coats, A. J. S., & Anker, S. D. (2000) · International Journal of Cardiology · doi:10.1016/s0167-5273(00)00224-2 · Cited by 144
Simvastatin Promotes Atherosclerotic Plaque Stability in ApoE-Deficient Mice Independently of Lipid Lowering
Bea, F., Blessing, E., Bennett, B. J., Levitz, M., Wallace, E. P., & Rosenfeld, M. E. (2002) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000036081.01231.16 · Cited by 144
Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups
Blasetto, J. W., Stein, E. A., Brown, W. V., Chitra, R., & Raza, A. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00003-1 · Cited by 143
Total and HDL cholesterol and risk of stroke. EUROSTROKE: a collaborative study among research centres in Europe
Bots, M. L., Elwood, P. C., Nikitin, Y., Salonen, J. T., Freire de Concalves, A., Inzitari, D., Sivenius, J., Benetou, V, Tuomilehto, J., Koudstaal, P. J., et al. (2002) · Journal of Epidemiology and Community Health · doi:10.1136/jech.56.suppl_1.i19 · Cited by 143
Simvastatin: a review
Pedersen, T. R., & Tobert, J. A. (2004) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.5.12.2583 · Cited by 147
Effect of Genetic Polymorphism of OATP-C (SLCO1B1) on Lipid-Lowering Response to HMG-CoA Reductase Inhibitors
Tachibana-Iimori, R., Tabara, Y., Kusuhara, H., Kohara, K., Kawamoto, R., Nakura, J., Tokunaga, K., Kondo, I., Sugiyama, Y., & Miki, T. (2004) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.19.375 · Cited by 144
Use of Statins and Blood Pressure Control in Treated Hypertensive Patients with Hypercholesterolemia
Borghi, C., Prandin, M. G., Costa, F. V., Bacchelli, S., Esposti, D. D., & Ambrosioni, E. (2000) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200004000-00006 · Cited by 144
Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study
Beest, F. J. A. P., Termorshuizen, F., Goettsch, W., Klungel, O. H., Kastelein, J. J. P., & Herings, R. M. C. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl391 · Cited by 145
Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment
Mensah, K., Mocanu, M. M., & Yellon, D. M. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.01.021 · Cited by 142
MRI and Characterization of Atherosclerotic Plaque
Choudhury, R. P., Fuster, V., Badimón, J. J., Fisher, E. A. A., & Fayad, Z. A. (2002) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000019735.54479.2f · Cited by 142
Statins and cardiovascular diseases: the multiple effects of lipid-lowering therapy by statins
Rauch, U., Osende, J., Chesebro, J. H., Fuster, V., Vorchheimer, D. A., Harris, K., Harris, P., Sandler, D. A., Fallon, J. T., Jayaraman, S., et al. (2000) · Atherosclerosis · doi:10.1016/s0021-9150(00)00397-x · Cited by 142
Hormone Replacement Therapy and Heart Disease Prevention
Petitti, D. B. (1998) · JAMA · doi:10.1001/jama.280.7.650 · Cited by 142
Clinical efficacy and safety of statins in managing cardiovascular risk
Kapur, N. K. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s1653 · Cited by 143
Statin use is associated with fewer periodontal lesions: A retrospective study
Lindy, O., Suomalainen, K., Mäkelä, M., & Lindy, S. (2008) · BMC Oral Health · doi:10.1186/1472-6831-8-16 · Cited by 143
Obesity and cardiovascular disease
Abate, N. I. (2000) · Journal of Diabetes and its Complications · doi:10.1016/s1056-8727(00)00067-2 · Cited by 144
Statins as potential therapeutic agents in neuroinflammatory disorders
Stüve, O., Youssef, S., Steinman, L., & Zamvil, S. S. (2003) · Current Opinion in Neurology · doi:10.1097/01.wco.0000073942.19076.d1 · Cited by 141
Dietary Lipid Lowering Reduces Tissue Factor Expression in Rabbit Atheroma
Aikawa, M., Voglic, S. J., Sugiyama, S., Aikawa, E. R., Taubman, M. B., Fallon, J. T., & Libby, P. (1999) · Circulation · doi:10.1161/01.cir.100.11.1215 · Cited by 141
From trial data to practical knowledge: qualitative study of how general practitioners have accessed and used evidence about statin drugs in their management of hypercholesterolaemia
Fairhurst, K., & Huby, G. Ø. (1998) · BMJ · doi:10.1136/bmj.317.7166.1130 · Cited by 141
Impact of gender in primary prevention of coronary heart disease with statin therapy: a meta-analysis
Petretta, M., Costanzo, P., Perrone-Filardi, P., & Chiariello, M. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2008.08.001 · Cited by 141
Residual atherosclerotic cardiovascular disease risk in statin-treated adults: The Multi-Ethnic Study of Atherosclerosis
Wong, N. D., Zhao, Y., Quek, R. G. W., Blumenthal, R. S., Budoff, M. J., Cushman, M., Garg, P. K., Sandfort, V., Tsai, M. Y., & López, J. A. G. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.06.015 · Cited by 142
Preoperative statin therapy is associated with reduced cardiac mortality after coronary artery bypass graft surgery
Collard, C. D., Body, S. C., Shernan, S. K., Wang, S. V., & Mangano, D. T. (2006) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2006.04.009 · Cited by 138
Changes in coronary plaque color and morphology by lipid-lowering therapy with atorvastatin: serial evaluation by coronary angioscopy
Takano, M., Mizuno, K., Yokoyama, S., Seimiya, K., Ishibashi, F., Okamatsu, K., & Uemura, R. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00770-8 · Cited by 140
The Friedewald Formula Underestimates LDL Cholesterol at low Concentrations
Scharnagl, H., Nauck, M. A., Wieland, H., & März, W. (2001) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2001.068 · Cited by 139
Clinical implications for statin pleiotropy
Liao, J. K. (2005) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000191913.16321.60 · Cited by 139
Long-term statin use and psychological well-being
Young‐Xu, Y., Chan, K. A., Liao, J. K., Ravid, S., & Blatt, C. M. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00785-x · Cited by 139
Obesity is associated with fatal coronary heart disease independently of traditional risk factors and deprivation
Logue, J., Murray, H. M., Welsh, P. I., Shepherd, J., Packard, C. J., Macfarlane, P. W., Cobbe, S. M., Ford, I., & Sattar, N. A. (2011) · Heart · doi:10.1136/hrt.2010.211201 · Cited by 139
UNRAVELLING THE GENETIC BASIS OF SUSCEPTIBILITY TO MYCOBACTERIAL INFECTION
Levin, M., & Newport, M. J. (1997) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199701)181:1 · Cited by 6
Integrating Heterogeneous Pieces of Evidence in Systematic Reviews
Mulrow, C. D., Langhorne, P., & Grimshaw, J. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-127-11-199712010-00008 · Cited by 132
Effects of hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury
Indolfi, C., Cioppa, A., Stabile, E., Lorenzo, E. D., Esposito, G., Pisani, A., Leccia, A., Cavuto, L., Stingone, A. M., Chieffo, A., et al. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00526-4 · Cited by 138
Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study
Kornblau, S. M., Banker, D. E., Stirewalt, D. L., Shen, D. D., Lemker, E., Verstovšek, S., Estrov, Z. E., Faderl, S. H., Cortes, J. E., Beran, M., et al. (2006) · Blood · doi:10.1182/blood-2006-08-044446 · Cited by 136
Lipid Lowering Promotes Accumulation of Mature Smooth Muscle Cells Expressing Smooth Muscle Myosin Heavy Chain Isoforms in Rabbit Atheroma
Aikawa, M., Aikawa, E. R., Voglic, S. J., et al. (1998) · Circulation Research · doi:10.1161/01.res.83.10.1015 · Cited by 139
Sex Bias and Underutilization of Lipid-Lowering Therapy in Patients With Coronary Artery Disease at Academic Medical Centers in the United States and Canada
Miller, M. J. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.3.343 · Cited by 138
Untitled work
Robinson (2012) · doi:10.1016/j.amjcard.2012.07.007 · Cited by 137
Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Additional perspectives on tolerability of long-term treatment with lovastatin
Downs, J. R., Clearfield, M., Tyroler, H. A., Whitney, E. J., Kruyer, W., Langendorfer, A., Zagrebelsky, V., Weis, S., Shapiro, D. R., Beere, P. A., et al. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01464-3 · Cited by 138
Effects of statins beyond lipid lowering: Potential for clinical benefits
Almuti, K., Rimawi, R., Spevack, D. M., & Ostfeld, R. J. (2005) · International Journal of Cardiology · doi:10.1016/j.ijcard.2005.05.056 · Cited by 139
Clinical and Economic Impact of Ambulatory Care Clinical Pharmacists in Management of Dyslipidemia in Older Adults: The IMPROVE Study
Ellis, S. L., Carter, B. L., Malone, D. C., Billups, S. J., Okano, G. J., Valuck, R. J., Barnette, D. J., Sintek, C. D., Covey, D. F., Mason, B. J., et al. (2000) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.20.19.1508.34852 · Cited by 138
Fluvastatin inhibits up‐regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells
Ferrara, D. E., Swerlick, R. A., Casper, K., Meroni, P. L., Vega-Ostertag, M. E., Harris, E. N., & Pierangeli, S. S. (2004) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2004.00896.x · Cited by 139
Effectiveness of Colesevelam Hydrochloride in Decreasing LDL Cholesterol in Patients With Primary Hypercholesterolemia: A 24-Week Randomized Controlled Trial
Insull, W., Toth, P. D., Mullican, W. S., Hunninghake, D. B., Burke, S. K., Donovan, J. M., & Davidson, M. H. (2001) · Mayo Clinic Proceedings · doi:10.4065/76.10.971 · Cited by 138
Columbia University's Informatics for Diabetes Education and Telemedicine (IDEATel) Project: Technical Implementation
Starren, J. B., Hripcsak, G. M., Sengupta, S., Abbruscato, C. R., Knudson, P. E., Weinstock, R. S., & Shea, S. A. (2002) · Journal of the American Medical Informatics Association · doi:10.1136/jamia.2002.0090025 · Cited by 138
Statins and Blockers of the Renin-Angiotensin System
Faggiotto, A., & Paoletti, R. (1999) · Hypertension · doi:10.1161/01.hyp.34.4.987 · Cited by 139
Lipoproteins and lipoprotein mimetics for imaging and drug delivery
Thaxton, C. S., Rink, J. S., Naha, P. C., & Cormode, D. P. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.020 · Cited by 142
High-sensitivity cardiac troponin assays for cardiovascular risk stratification in the general population
Farmakis, D. T., Mueller, C. E., & Apple, F. S. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa083 · Cited by 138
Diverse effects of inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase on the expression of VCAM-1 and E-selectin in endothelial cells
Rasmussen, L. M., Hansen, P. R., NABIPOUR, M. T., Olesen, P., Kristiansen, M. T., & Ledet, T. (2001) · Biochemical Journal · doi:10.1042/0264-6021:3600363 · Cited by 134
Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis
Doornum, S. V., McColl, G., & Wicks, I. P. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.018333 · Cited by 138
An Analysis of Nine Proprietary Chinese Red Yeast Rice Dietary Supplements: Implications of Variability in Chemical Profile and Contents
Heber, D., Lembertas, A. V., Lu, Q., Bowerman, S., & Go, V. L. W. (2001) · The Journal of Alternative and Complementary Medicine · doi:10.1089/107555301750164181 · Cited by 137
Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia.
Bertolini, S., Bon, G., Campbell, L., Farnier, M., Langan, J., Mahla, G., Pauciullo, P., Sirtori, C., Egros, F., Fayyad, R., et al. (1997) · Atherosclerosis · doi:10.1016/s0021-9150(96)06052-2 · Cited by 140
Non-adherence to statin therapy: a major challenge for preventive cardiology
Bates, T., Connaughton, V., & Watts, G. F. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903376186 · Cited by 137
Multicenter clinical trial of the serum lipid-lowering effects of a Monascus purpureus (red yeast) rice preparation from traditional Chinese medicine
Wang, J., Lu, Z., Chi, J., Wang, W., Su, M., Kou, W., Yu, P., Yu, L., Chen, L., Zhu, J., et al. (1997) · Current Therapeutic Research · doi:10.1016/s0011-393x(97)80063-x · Cited by 136
Statin Use and the Risk of Breast and Prostate Cancer
Coogan, P. F., Rosenberg, L. A., Palmer, J. R., Strom, B. L., Zauber, A. G., & Shapiro, S. (2002) · Epidemiology · doi:10.1097/00001648-200205000-00005 · Cited by 137
Micronised Fenofibrate
Adkins, J. C., & Faulds, D. M. (1997) · Drugs · doi:10.2165/00003495-199754040-00007 · Cited by 137
Pitavastatin: Efficacy and Safety Profiles of A Novel Synthetic HMG‐CoA Reductase Inhibitor
Kajinami, K., Takekoshi, N., & Saito, Y. (2003) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2003.tb00116.x · Cited by 136
Effect of Pravastatin on Angiographic Restenosis After Coronary Balloon Angioplasty fn1fn1This study was supported by a grant from Bristol Myers Squibb Laboratories, Paris.
Bertrand, M. E., McFadden, E. P., Fruchart, J., BELLE, E. V., Commeau, P., Grollier, G., Bassand, J., Machecourt, J., Cassagnes, J., Mossard, J.-M., et al. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(97)00259-3 · Cited by 135
Performance indicators for primary care groups: an evidence based approach
McColl, A., Roderick, P., Gabbay, J., Smith, H. E., & Moore, M. V. (1998) · BMJ · doi:10.1136/bmj.317.7169.1354 · Cited by 135
Joint British recommendations on prevention of coronary heart disease in clinical practice. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association.
(1998) · Europe PMC (PubMed Central) · Cited by 143
Additive effects of Simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients
Tonolo, G., Melis, M. G., Formato, M., Angius, M. F., Carboni, A., Brizzi, P., Ciccarese, M., Cherchi, G. M., & Maioli, M. (2000) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2000.00735.x · Cited by 135
CKD and Sudden Cardiac Death
Whitman, I. R., Feldman, H. I., & Deo, R. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012010037 · Cited by 132
Chronic Kidney Disease Japan Cohort (CKD-JAC) Study: Design and Methods
Imai, E., Matsuo, S., Makino, H., Watanabe, T., Akizawa, T., Nitta, K., Iimuro, S., Ohashi, Y., & Hishida, A. (2008) · Hypertension Research · doi:10.1291/hypres.31.1101 · Cited by 134
What role for statins? A review and economic model.
Ebrahim, S. B. J., Smith, G. D., McCabe, Payne, Pickin, Sheldon, T., Lampe, F. C., Sampson, F. C., Ward, S. E., & Wannamethee, S. G. (1999) · Health Technology Assessment · doi:10.3310/hta3190 · Cited by 134
Inclusion of Stroke in Cardiovascular Risk Prediction Instruments
Lackland, D. T., Elkind, M. S. V., D’Agostino, R. B., Dhamoon, M. S., Goff, D. C., Higashida, R. T., McClure, L. A., Mitchell, P. H., Sacco, R. L., Sila, C. A., et al. (2012) · Stroke · doi:10.1161/str.0b013e31825bcdac · Cited by 136
Heart Failure as a Risk Factor for Stroke
Kim, W., & Kim, E. J. (2018) · Journal of Stroke · doi:10.5853/jos.2017.02810 · Cited by 137
Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor
Jones, S. P., Gibson, M. F., Rimmer, D. M., Gibson, T. M., Sharp, B. R., & Lefer, D. J. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02115-0 · Cited by 133
Factors associated with low compliance with lipid-lowering drugs in hyperlipidemic patients
Kiortsis, D. N., Giral, P., Bruckert, É., & Turpin, G. (2000) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.2000.00315.x · Cited by 133
Effects of statins on stroke prevention in patients with and without coronary heart disease: A meta-analysis of randomized controlled trials
Briel, M., Studer, M., Glass, T. R., & Bucher, H. C. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.04.022 · Cited by 134
Targeting Low HDL-Cholesterol to Decrease Residual Cardiovascular Risk in the Managed Care Setting
Cziraky, M. J., Watson, K. E., & Talbert, R. L. (2008) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2008.14.s8-a.1 · Cited by 134
Epidemiologic evidence for high-density lipoprotein cholesterol as a risk factor for coronary artery disease
Franceschini, G. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)02146-4 · Cited by 131
Increased Angiotensin II Type 1 Receptor Expression in Hypercholesterolemic Atherosclerosis in Rabbits
Yang, B., Phillips, M. I., Mohuczy, D., Meng, H., Shen, L., Mehta, P., & Mehta, J. L. (1998) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.18.9.1433 · Cited by 132
Sheffield risk and treatment table for cholesterol lowering in prevention of coronary heart disease.
Megnien, J. L., Levenson, J. A., & Simon, A. C. (1996) · PubMed · Cited by 132
Enrichment of Clinical Study Populations
Temple, R. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.233 · Cited by 131
The Use of Statins and Lung Function in Current and Former Smokers
Keddissi, J. I., Younis, W. G., Chbeir, E. A., et al. (2007) · CHEST Journal · doi:10.1378/chest.07-0298 · Cited by 131
Prevention of Cardiovascular Events with Omega-3 Polyunsaturated Fatty Acids and the Mechanism Involved
Watanabe, Y., & Tatsuno, I. (2019) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.50658 · Cited by 135
Sunlight, cholesterol and coronary heart disease
Grimes, D. S., Hindle, E. J., & Dyer, T. (1996) · QJM · doi:10.1093/qjmed/89.8.579 · Cited by 131
Application of a Diabetes Managed Care Program: The feasibility of using nurses and a computer system to provide effective care
Peters, A. L., & Davidson, M. B. (1998) · Diabetes Care · doi:10.2337/diacare.21.7.1037 · Cited by 131
Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats
Schaefer, W. H., Lawrence, J. W., Loughlin, A. F., Stoffregen, D. A., Mixson, L. A., Dean, D. C., Raab, C. E., Yu, N. X., Lankas, G. R., & Frederick, C. B. (2003) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2003.08.013 · Cited by 131
The effect of combining plant sterols, soy protein, viscous fibers, and almonds in treating hypercholesterolemia
Jenkins, D. J. A., Kendall, C. W. C., Marchie, A., Faulkner, D., Vidgen, E., Lapsley, K. G., Trautwein, E. A., Parker, T. L., Josse, R. G., Leiter, L. A., et al. (2003) · Metabolism · doi:10.1016/s0026-0495(03)00260-9 · Cited by 131
Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia
Szczeklik, A., Musiał, J., Undas, A., et al. (1999) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00023-6 · Cited by 131
Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease
Horne, B. D., Muhlestein, J. B., Carlquist, J. F., Bair, T. L., Madsen, T. E., Hart, N. I., & Anderson, J. L. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00950-5 · Cited by 131
Evaluation of Time to Benefit of Statins for the Primary Prevention of Cardiovascular Events in Adults Aged 50 to 75 Years: A Meta-analysis
Yourman, L. C., Cenzer, I. S., Boscardin, W. J., Nguyen, B. T., Smith, A. K., Schonberg, M. A., Schoenborn, N. L., Widera, E. W., Orkaby, A., Rodriguez, A., et al. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.6084 · Cited by 133
Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease
Robinson, E., & Grieve, D. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.03.003 · Cited by 132
Atherosclerotic risk factor reduction in peripheral arterial disease
McDermott, M., Hahn, E., Greenland, P., Cella, D., Ockene, J., Brogan, D. J., Pearce, W., Hirsch, A., Hanley, K., Odom, L., et al. (2002) · Journal of general internal medicine · doi:10.1046/j.1525-1497.2002.20307.x · Cited by 127
Downregulation of Angiotensin II Type 1 Receptor by Hydrophobic 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors in Vascular Smooth Muscle Cells
Ichiki, T., Takeda, K., Tokunou, T., Iino, N., Egashira, K., Shimokawa, H., Hirano, K., Kanaide, H., & Takeshita, A. (2001) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/hq1201.099430 · Cited by 130
The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys
van Heek, M., Compton, D. S., & Davis, H. R. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)00825-1 · Cited by 131
Chitosan decreases total cholesterol in women: a randomized, double-blind, placebo-controlled trial
Bokura, H., & KOBAYASHI, S. (2003) · European Journal of Clinical Nutrition · doi:10.1038/sj.ejcn.1601603 · Cited by 130
Cardiovascular Risk and Renal Transplantation: Post Hoc Analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study
Jardine, A. G., Fellström, B., Logan, J. O., et al. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.05.014 · Cited by 130
European Stroke Initiative Recommendations for Stroke Management
(2000) · Cerebrovascular Diseases · doi:10.1159/000016089 · Cited by 128
Association between statin use and colorectal cancer risk: a meta-analysis of 42 studies
Liu, Y., Tang, W., Wang, J., Xie, L., Li, T., He, Y., Deng, Y., Peng, Q., Li, S., & Qin, X. Y. (2013) · Cancer Causes & Control · doi:10.1007/s10552-013-0326-6 · Cited by 132
Nanomaterials towards fabrication of cholesterol biosensors: Key roles and design approaches
Saxena, U., & Das, A. B. (2015) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2015.08.042 · Cited by 128
“…and may lead to an increased chance of developing a range of life-threatening cardiac and brain vascular diseases such as hypertension, arteriosclerosis, coronary heart disease, lipid metabolism dysfunction, brain thrombosis etc. (Nauck et al., 2000; Shepherd et al., 1995; Stapleton et al., 2010).”
Background
The importance of LDL-C lowering in atherosclerotic cardiovascular disease prevention: Lower for longer is better
Mhaimeed, O., Burney, Z. A., Schott, S. L., Kohli, P., Marvel, F. A., & Martin, S. S. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100649 · Cited by 140
“The following year, the WOSCOPS trial of pravastatin versus placebo demonstrated a primary prevention benefit in men with hyperlipidemia, defined as a fasting LDL-C level of 155 mg/dL or more despite appropriate dietary strategies [43].”
Background
Stimulation of inflammatory responses in vitro and in vivo by lipophilic HMG-CoA reductase inhibitors
Kiener, P. A., Davis, P. M., Murray, J. L., Youssef, S., Rankin, B. M., & Kowala, M. C. (2001) · International Immunopharmacology · doi:10.1016/s0162-3109(00)00272-1 · Cited by 128
Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors
Moghadasian, M. H. (1999) · Life Sciences · doi:10.1016/s0024-3205(99)00199-x · Cited by 128
Antiinflammatory and Antiarteriosclerotic Actions of HMG-CoA Reductase Inhibitors in a Rat Model of Chronic Inhibition of Nitric Oxide Synthesis
Ni, W., Egashira, K., Kataoka, C., Kitamoto, S., Koyanagi, M., Inoue, S., & Takeshita, A. (2001) · Circulation Research · doi:10.1161/hh1701.096614 · Cited by 129
Intravascular Ultrasound Analysis of Reduction in Progression of Coronary Narrowing by Treatment With Pravastatin
Takagi, T., Yoshida, K., Akasaka, T., Hozumi, T., Morioka, S., & Yoshikawa, J. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00221-x · Cited by 129
Rosuvastatin Demonstrates Greater Reduction of Low-Density Lipoprotein Cholesterol Compared with Pravastatin and Simvastatin in Hypercholesterolaemic Patients: A Randomized, Double-Blind Study
Paoletti, R., Fahmy, M. I., Mahla, G., Mizan, J., & Southworth, H. (2001) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1177/174182670100800608 · Cited by 129
Stroke prevention, blood cholesterol, and statins
Amarenco, P., Lavallée, P. C., & Touboul, P. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00734-3 · Cited by 129
Variations in Cholesterol Management Practices of U.S. Physicians
Stafford, R. S., Blumenthal, D., & Pasternak, R. C. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(96)00441-x · Cited by 129
Approach to lipoprotein management in 2001 National Cholesterol Guidelines
Grundy, S. M. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02631-0 · Cited by 128
Inflammatory Biomarkers and Risks of Myocardial Infarction, Stroke, Diabetes, and Total Mortality: Implications for Longevity
Ridker, P. M. (2008) · Nutrition Reviews · doi:10.1111/j.1753-4887.2007.tb00372.x · Cited by 132
Lipoproteins, Platelets, and Atherothrombosis
Badimón, L., Vilahur, G., & Padró, T. (2009) · Revista Española de Cardiología (English Edition) · doi:10.1016/s1885-5857(09)73331-6 · Cited by 128
The role of fibrates in the prevention of cardiovascular disease—a pooled meta-analysis of long-term randomized placebo-controlled clinical trials
Saha, S. A., Kizhakepunnur, L. G., Bahekar, A., & Arora, R. R. (2007) · American Heart Journal · doi:10.1016/j.ahj.2007.07.011 · Cited by 129
Microalbuminuria is independently associated with ischaemic electrocardiographic abnormalities in a large non-diabetic population. The PREVEND (Prevention of REnal and Vascular ENdstage Disease) study
Diercks, G. F. H. (2000) · European Heart Journal · doi:10.1053/euhj.2000.2248 · Cited by 128
Statin therapy is associated with reduced mortality across all age groups of individuals with significant coronary disease, including very elderly patients
Maycock, C. A. A., Muhlestein, J. B., Horne, B. D., Carlquist, J. F., Bair, T. L., Pearson, R. R., Li, Q., & Anderson, J. L. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02477-4 · Cited by 127

Authors: Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J.
Affiliations: Glasgow Royal Infirmary (GB)
University of Glasgow (GB)
NHS Dumfries and Galloway (GB)
ORCID: Ford, Ian
Macfarlane, Peter W.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 1995-11-16
Volume: 333
Issue: 20
Pages: 1301-1308
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm199511163332001
OpenAlex: W2155598961
Semantic Scholar: 1aa5f64bbe1d0c4c74fc3de7c89ac2dffb48630a
Cited by: 7,449
References: 26
Citations by year: 2026: 31 · 2025: 33 · 2024: 56 · 2023: 54 · 2022: 66 · 2021: 72 · 2020: 95 · 2019: 90 · 2018: 108 · 2017: 121 · 2016: 157 · 2015: 137 · 2014: 177 · 2013: 215 · 2012: 197
FWCI: 344.87
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: Bristol-Myers Squibb
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords: pravastatin, hypercholesterolemia, coronary heart disease prevention, statins, LDL cholesterol lowering, nonfatal myocardial infarction, cardiovascular mortality, men, cholesterol-lowering therapy
MeSH terms: Anticholesteremic Agents, Cholesterol, Coronary Disease, Double-Blind Method, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Middle Aged, Myocardial Infarction, Neoplasms, Risk, Incidence, Survival Analysis, Pravastatin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks